Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Clin Pharmacol Ther. 2017 Nov 28;103(2):233–242. doi: 10.1002/cpt.903

Figure 1.

Figure 1

Chemotherapeutics that have shown to be BCRP substrates are summarized by their approved indications. These compounds are at risk for multi-drug resistance and may benefit from the concomitant use of BCRP inhibitors in the clinic. Sources for each chemotherapy can be found in the Supplemental Table S1. Adapted and printed with permission from Designua/Shutterstock.com.